CYTH News and Press, Cyclo Therapeutics Inc. From 11/17/21

Gainers: InMed Pharmaceuticals (NASDAQ:INM) +47%, EyePoint Pharmaceuticals (NASDAQ:EYPT) +24%, Varex Imaging (NASDAQ:VREX) +12%, OptiNose (NASDAQ:OPTN) +10%, Talkspace (NASDAQ:TALK) +7%. Losers: Cassava Sciences (NASDAQ:SAVA) -26%, Eloxx Pharm...

Cyclo Therapeutics (NASDAQ:CYTH) has priced its public offering of 1.95M  shares of common stock at $6.00/share, for expected gross proceeds of $11.7M. Underwriter's over-allotment is an additional 292.5K shares. Maxim Group is acting as sole book-running manager. Earlier, CYTH stock gai...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH, CYTHW) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today...

Cyclo Therapeutics (NASDAQ:CYTH) trades 15.3% down after hours on commencing an underwritten public offering of shares. Offer size, terms have not yet been disclosed. For further details see: Cyclo Therapeutics under pressure on launching stock offering

Cyclo Therapeutics, Inc. (Nasdaq: CYTH, CYTHW) (“Cyclo Therapeutics” of the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today...

Kezar Life Sciences (NASDAQ:KZR) +46% on phase 2 data for lupus candidate Axon Enterprise (NASDAQ:AXON) +24% on Q3 results Cyclo Therapeutics (NASDAQ:CYTH) +19% on Q3 results. Comstock Holding Companies (NASDAQ:CHCI) +20% on Q3 results. Romeo Power (NYS...

Cyclo Therapeutics (NASDAQ:CYTH) soars 18% premarket after submitting its initial investigational new drug (IND) application to the FDA for a Phase 2 study of Trappsol Cyclo for the treatment of early Alzheimer’s Disease (AD). “The feedback and recommendation...

– Biologic similarities demonstrated between Niemann-Pick Disease Type C and Alzheimer’s Disease, including cholesterol accumulation in regions of the brain, elevated levels of Tau in CSF, and amyloid plaques in the brain, bolsters rationale for studying Trappsol &...

By reducing cholesterol levels, Trappsol Cyclo may impede the onset and early progression of Alzheimer's disease. By scavenging peroxynitrite, Trappsol Cyclo can potentially reverse part of the damage that occurs to the brain during Alzheimer's disease. Cyclo Therapeutics has a hi...

Cyclo Therapeutics (NASDAQ:CYTH): Q3 GAAP EPS of -$0.60 beats by $0.07. Revenue of $0.4M (+81.8% Y/Y) beats by $0.02M. Press Release For further details see: Cyclo Therapeutics EPS beats by $0.07, beats on revenue